Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC

NCT ID: NCT07085169

Last Updated: 2025-07-25

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-08-01
• Study Completion Date: 2028-08-01

Brief Summary

This is a phase II, single-center, prospective trial aimed to investigate the efficacy and safety of a modified regimen of trifluridine/tipiracil plus bevacizumab in refractory metastatic colorectal cancer. Patients will be treated with trifluridine/tipiracil (17.5 mg/m2 dose orally twice daily, d1-10, every 14-days) plus bevacizumab (5mg/kg dose intravenously once at day 1, every 14-days). The study treatment will be administered until progression of disease, intolerable toxicity or withdraw of consent.

Detailed Description

The treatment options as third-line therapy for metastatic colorectal cancer patients are limited. Trifluridine/tipiracil (TAS-102) plus bevacizumab has been approved in colorectal cancer for patients who are refractory to or intolerant of standard chemotherapy. However, the toxicity of trifluridine/tipiracil at standard dose a clinical concerned issue. Modifications of dose and treatment cycle of trifluridine/tipiracil have been investigated, and show promising effect to reduce the toxicity. In this study, patients with refractory metastatic colorectal cancer who have disease progression after at least 2 standard regimens will be treated with low-dose trifluridine/tipiracil plus bevacizumab. Trifluridine/tipiracil will be given at a 17.5 mg/m2 dose orally twice daily in a 14-day cycle consisting of 10 treatment days/4 rest days. Bevacizumab will be given at a 5mg/kg dose intravenously once at day 1 in a 14-day cycle. This regimen will be administered until progression of disease, intolerable toxicity or withdraw of consent.

Conditions

Colo-rectal Cancer; Third-line and Beyond Therapy; TAS 102; Bevacizumab

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Experimental

Trifluridine/tipiracil 17.5 mg/m2 bid. po. d1-10, q2w Bevacizumab 5mg/kg ivgtt. d1 q2w

Group Type: EXPERIMENTAL

Trifluridine/tipiracil (TAS-102) plus bevacizumab

Intervention Type: DRUG

Trifluridine/tipiracil will be given at a 17.5 mg/m2 dose orally twice daily in a 14-day cycle consisting of 10 treatment days/4 rest days. Bevacizumab will be given at a 5mg/kg dose intravenously once at day 1 in a 14-day cycle. This is a single-arm study with all patients receiving these two drugs.

Interventions

Trifluridine/tipiracil (TAS-102) plus bevacizumab

Trifluridine/tipiracil will be given at a 17.5 mg/m2 dose orally twice daily in a 14-day cycle consisting of 10 treatment days/4 rest days. Bevacizumab will be given at a 5mg/kg dose intravenously once at day 1 in a 14-day cycle. This is a single-arm study with all patients receiving these two drugs.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. age over 60 years old, male and female

2. histologically confirmed adenocarcinoma of the colon or rectum

3. patients with metastatic or advanced unresectable diseases who had received two or more previous chemotherapy regimens or intolerance to last regimen

4. with or without measurable lesions

5. ECOG 0 to 2, expected survival time over 3 months

6. Enough organ functions that can tolerate treatment: Absolute neutrophil count (ANC) ≥1.5x109/L, White blood count ≥3.5x109/L, Platelets ≥75x109/L, Hemoglobin (Hb) ≥80g/L, ALT/AST ≤2.5x ULN (for patient with liver metastasis ALT/AST ≤5x ULN), Serum bilirubin ≤1.5x ULN, Serum creatinine ≤1.5x ULN.

7. Signed informed consent and willing to follow the study protocol

Exclusion Criteria

1. symptomatic metastases of central nervous system

2. other primary malignancies

3. uncontrollable comorbidities, such as hypertension, thrombotic diseases, chronic kidney disease

4. organ functions that cannot tolerate study treatment

5. bowel obstruction or other conditions affecting oral administration

6. allergic to study medication

7. other conditions that patients are unsuitable for this study assessed by the investigators

• Minimum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ruijin Hospital

OTHER

Sponsor Role: lead

Responsible Party

Jun Zhang

Clinical Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

SanMing First Hospital

Sanming, , China

Site Status: RECRUITING

Ruijin Hospital

Shanghai, , China

Site Status: RECRUITING

Countries

China

Central Contacts

Chen-Fei Zhou, MD, Ph.D

Role: CONTACT

zcf12085@rjh.com.cn

+86-21-64370045

Other Identifiers

TAS-102/2025-No.412

Identifier Type: -

Identifier Source: org_study_id